Literature DB >> 1664132

Role of antibody-dependent cellular cytotoxicity in neonatal infection with herpes simplex virus.

S Kohl1.   

Abstract

The role of antibody and, in particular, antibody-dependent cellular cytotoxicity (ADCC) antibodies, in preventing or reducing the severity of infection with herpes simplex virus (HSV) in neonates is controversial. We have shown that human and murine neonates, in contrast with adults, are relatively deficient in ADCC leukocyte effector cell function. In an adoptive transfer model, the combination of ADCC-active human leukocytes and antibody to HSV could protect neonatal mice from lethal infection with HSV. Use of cells defective in ADCC function (e.g., from human neonates or patients with the CD11,18 deficiency in cell surface adhesive integrin) could not provide protection in this model. Finally, in human neonates the level of ADCC antibody at the time of infection with HSV was associated with severity of illness. Thus, ADCC is an important host defense against neonatal infection with HSV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1664132     DOI: 10.1093/clind/13.supplement_11.s950

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  16 in total

1.  Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity.

Authors:  Chaya D Patel; Iara M Backes; Sean A Taylor; Yike Jiang; Arnaud Marchant; Jean M Pesola; Donald M Coen; David M Knipe; Margaret E Ackerman; David A Leib
Journal:  Sci Transl Med       Date:  2019-04-10       Impact factor: 17.956

2.  Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.

Authors:  Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

3.  Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1.

Authors:  S Vollstedt; M Franchini; G Alber; M Ackermann; M Suter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro.

Authors:  Z Mikloska; P P Sanna; A L Cunningham
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates.

Authors:  Christopher D Petro; Brian Weinrick; Nazanin Khajoueinejad; Clare Burn; Rani Sellers; William R Jacobs; Betsy C Herold
Journal:  JCI Insight       Date:  2016-08-04

6.  Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads.

Authors:  Pratip Nag; Jenney Kim; Vytautas Sapiega; Alan L Landay; James W Bremer; Jiri Mestecky; Patricia Reichelderfer; Andrea Kovacs; Jonathan Cohn; Barbara Weiser; Linda L Baum
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

7.  Transplacental transfer and subsequent neonate utilization of herpes simplex virus-specific immunity are resilient to acute maternal stress.

Authors:  Jodi L Yorty; Robert H Bonneau
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 8.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

9.  Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.

Authors:  Kening Wang; Lesia Dropulic; Joel Bozekowski; Harlan L Pietz; Sinthujan Jegaskanda; Kennichi Dowdell; Joshua S Vogel; Doreen Garabedian; Makinna Oestreich; Hanh Nguyen; Mir A Ali; Keith Lumbard; Sally Hunsberger; Jack Reifert; Winston A Haynes; Jaymie R Sawyer; John C Shon; Patrick S Daugherty; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2021-11-16       Impact factor: 5.226

Review 10.  The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention.

Authors:  Soren Gantt; William J Muller
Journal:  Clin Dev Immunol       Date:  2013-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.